Effects of Erlotinib Therapy on [(11)C]erlotinib Uptake in EGFR Mutated, Advanced NSCLC

Overview

Journal EJNMMI Res

Date 2016 Feb 10

PMID 26857779

Citations 16

Authors

Idris Bahce

Maqsood Yaqub

Hanane Errami

Robert C Schuit

Patrick Schober

Erik Thunnissen

Albert D Windhorst

Adriaan A Lammertsma

Egbert F Smit

N Harry Hendrikse

Affiliations

Soon will be listed here.

Abstract

Background: In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron emission tomography (PET) using [(11)C]erlotinib distinguished epidermal growth factor receptor (EGFR) mutations from wild-type EGFR. However, tumor uptake of [(11)C]erlotinib during erlotinib therapy is unknown. Therefore, the aims of this study were to evaluate tumor [(11)C]erlotinib uptake in NSCLC patients both on and off erlotinib therapy, to evaluate the effect of erlotinib therapy on tumor perfusion and its correlation to tumor [(11)C]erlotinib uptake, and also, to investigate simplified uptake parameters using arterial and venous blood samples.

Methods: Ten patients were to be scanned twice with a 1-2-week interval, i.e., on (E+) and off (E-) erlotinib therapy. Each procedure consisted of a low-dose CT scan, a 10-min dynamic [(15)O]H2O PET scan, and a 60-min dynamic [(11)C]erlotinib PET scan with arterial and venous sampling at six time points. In patients(E+), the optimal compartment model was analyzed using Akaike information criterion. In patients(E-), the uptake parameter was the volume of distribution (V T), estimated by using metabolite-corrected plasma input curves based on image-derived input functions and discrete arterial and venous blood samples. Tumor blood flow (TBF) was determined by rate constant of influx (K1) of [(15)O]H2O using the 1T2k model and correlated with V T and K1 values of [(11)C]erlotinib. The investigated simplified parameters were standardized uptake value (SUV) and tumor-to-blood ratio (TBR) at 40-60 min pi interval.

Results: Of the 13 patients included, ten were scanned twice. In patients(E+), [(11)C]erlotinib best fitted the 2T4k model with V T. In all patients, tumor V T(E+) was lower than V T(E-) (median V T(E-) = 1.61, range 0.77-3.01; median V T(E+) = 1.17, range 0.53-1.74; P = 0.004). Using [(15)O]H2O, five patients were scanned twice. TBF did not change with erlotinib therapy, TBF showed a positive trend towards correlation with [(11)C]erlotinib K1, but not with V T. TBR40-50 and TBR50-60, using both arterial and venous sampling, correlated with V T(E-) (all r s >0.9, P < 0.001), while SUV did not. In patients off and on therapy, venous TBR underestimated arterial TBR by 26 ± 12 and 9 ± 9 %, respectively.

Conclusions: In patients on erlotinib in therapeutic dose, tumor V T decreases with high variability, independent of tumor perfusion. For simplification of [(11)C]erlotinib PET scanning protocols, both arterial and venous TBR 40-60 min post injection can be used; however, arterial and venous TBR values should not be interchanged as venous values underestimate arterial values.

Trial Registration: Registered at the Netherlands Trial Registry: NTR3670 .

Citing Articles

Advances in PET imaging of cancer.

Schwenck J, Sonanini D, Cotton J, Rammensee H, Fougere C, Zender L Nat Rev Cancer. 2023; 23(7):474-490.

PMID: 37258875 DOI: 10.1038/s41568-023-00576-4.

Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

Hu N, Yan G, Wu Y, Wang L, Wang Y, Xiang Y Front Oncol. 2022; 12:879341.

PMID: 36276079 PMC: 9582655. DOI: 10.3389/fonc.2022.879341.

PET Imaging of EGFR Expression: An Overview of Radiolabeled EGFR TKIs.

Zhu J, Li Y, Wu X, Li Y, Wang L, Fan H Curr Top Med Chem. 2022; 22(28):2329-2342.

PMID: 36056825 DOI: 10.2174/1568026622666220903142416.

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients.

Bartelink I, van de Stadt E, Leeuwerik A, Thijssen V, Hupsel J, van den Nieuwendijk J Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890095 PMC: 9315544. DOI: 10.3390/ph15070796.

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Crisan G, Moldovean-Cioroianu N, Timaru D, Andries G, Cainap C, Chis V Int J Mol Sci. 2022; 23(9).

PMID: 35563414 PMC: 9103893. DOI: 10.3390/ijms23095023.

References

Bahce I, Smit E, Lubberink M, van der Veldt A, Yaqub M, Windhorst A . Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res. 2012; 19(1):183-93. DOI: 10.1158/1078-0432.CCR-12-0289. View

Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M . PET kinetic analysis--compartmental model. Ann Nucl Med. 2007; 20(9):583-8. DOI: 10.1007/BF02984655. View

Weber B, Winterdahl M, Memon A, Sorensen B, Keiding S, Sorensen L . Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011; 6(7):1287-9. DOI: 10.1097/JTO.0b013e318219ab87. View

Mammatas L, Verheul H, Hendrikse N, Yaqub M, Lammertsma A, Menke-van der Houven van Oordt C . Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol (Dordr). 2014; 38(1):49-64. DOI: 10.1007/s13402-014-0194-4. View

Wang H, Yu J, Yang G, Song X, Sun X, Zhao S . Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci. 2007; 98(9):1413-6. PMC: 11160051. DOI: 10.1111/j.1349-7006.2007.00562.x. View

Memon A, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen H . PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer. 2011; 105(12):1850-5. PMC: 3251890. DOI: 10.1038/bjc.2011.493. View

Slobbe P, Windhorst A, Stigter-van Walsum M, Smit E, Niessen H, Solca F . A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. EJNMMI Res. 2015; 5:14. PMC: 4385286. DOI: 10.1186/s13550-015-0088-0. View

van der Veldt A, Hendrikse N, Harms H, Comans E, Postmus P, Smit E . Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med. 2010; 51(11):1684-90. DOI: 10.2967/jnumed.110.079137. View

Abourbeh G, Itamar B, Salnikov O, Beltsov S, Mishani E . Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET. EJNMMI Res. 2015; 5:4. PMC: 4385014. DOI: 10.1186/s13550-014-0080-0. View

10.

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

11.

Gunn R, Gunn S, Cunningham V . Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001; 21(6):635-52. DOI: 10.1097/00004647-200106000-00002. View

12.

Lammertsma A, Bench C, Hume S, Osman S, Gunn K, Brooks D . Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996; 16(1):42-52. DOI: 10.1097/00004647-199601000-00005. View

13.

Arcila M, Nafa K, Chaft J, Rekhtman N, Lau C, Reva B . EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013; 12(2):220-9. PMC: 3714231. DOI: 10.1158/1535-7163.MCT-12-0620. View

14.

Surti S, Kuhn A, Werner M, Perkins A, Kolthammer J, Karp J . Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med. 2007; 48(3):471-80. View

15.

Masago K, Fujita S, Irisa K, Kim Y, Ichikawa M, Mio T . Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol. 2010; 40(11):1105-9. DOI: 10.1093/jjco/hyq087. View

16.

Petrulli J, Sullivan J, Zheng M, Bennett D, Charest J, Huang Y . Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Neoplasia. 2014; 15(12):1347-53. PMC: 3884525. DOI: 10.1593/neo.131666. View

17.

Iqbal R, Kramer G, Verwer E, Huisman M, de Langen A, Bahce I . Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET. J Nucl Med. 2015; 57(4):530-5. DOI: 10.2967/jnumed.115.166579. View

18.

Pao W, Chmielecki J . Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010; 10(11):760-74. PMC: 3072803. DOI: 10.1038/nrc2947. View

19.

Han B, Zhou X, Zhang R, Zang W, Chen Z, Song H . Mutations of the epidermal growth factor receptor gene in NSCLC patients. Oncol Lett. 2012; 2(6):1233-1237. PMC: 3406548. DOI: 10.3892/ol.2011.366. View

20.

Ong M, Kwan K, Kamel-Reid S, Vincent M . Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation. Curr Oncol. 2012; 19(3):e222-6. PMC: 3364785. DOI: 10.3747/co.19.908. View